Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Therapy of Paediatric B-ALL with a Fast Off Rate CD19 CAR Leads to Enhanced Expansion and Prolonged CAR T Cell Persistence in Patients with Low Bone Marrow Tumour Burden, and Is Associated with a Favourable Toxicity Profile

Blood (2019) 134 (Supplement_1): 225.

https://doi.org/10.1182/blood-2019-125009

Published: 2019

Journal Articles

Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study

Kirit M. Ardeshna, MBBChir, Maria A V Marzolini, Jane Norman, MD, Muhammad Al-Hajj, Simon Thomas, PhD, Jim Faulkner, Ekaterini Kotsopoulou, Martin Pule, MD, Vijay G R Peddareddigari, Nushmia Z Khokhar, Maud Jonnaert, PhD, Robert Chen, MD, Wendy Osborne, MD

Blood (2019) 134 (Supplement_1): 246.

https://doi.org/10.1182/blood-2019-122724

Published: 2019

Journal Articles

Generation of a Highly Sensitive CD22 CAR

Evangelia K Kokalaki, Biao Ma, PhD, Thomas Grothier, MSc, Warren Hazelton, MSc, Eren Costu, BSc, Somayya Manzoor, MSc, Ram Jha, MSc, Simon Thomas, PhD, Shimobi Onuoha, PhD, Shaun P Cordoba, PhD, Martin Pule, MD

Blood (2019) 134 (Supplement_1): 5747.

https://doi.org/10.1182/blood-2019-128002

Published: 2019

Journal Articles

Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study

Persis J Amrolia, FRCP, FRCPath, PhD, Robert Wynn, MD, Rachael E Hough, MD, Ajay Vora, Denise Bonney, Paul Veys, MD PhD, Robert Chiesa, Kanchan Rao, Liz Clark, Muhammad Al-Hajj, Shaun P Cordoba, PhD, Shimobi Onuoha, PhD, Ekaterini Kotsopoulou, Nushmia Z Khokhar, Martin Pule, MD, Vijay G R Peddareddigari

Blood (2019) 134 (Supplement_1): 2620.

https://doi.org/10.1182/blood-2019-123424

Published: 2019

Journal Articles

Phase 1 First-in-Human Study of AUTO2, the First Chimeric Antigen Receptor (CAR) T Cell Targeting APRIL for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Rakesh Popat, Sonja Zweegman, MD PhD, Jim Cavet, FRCPath, Kwee Yong, Lydia Lee, Jim Faulkner, Ekaterini Kotsopoulou, Muhammad Al-Hajj, Simon Thomas, PhD, Shaun P Cordoba, PhD, Martin Pule, MD, Virginie Cerec, PhD, Vijay G R Peddareddigari, Nushmia Z Khokhar, MD, Tobias F Menne, MD PhD FRCPath

Blood (2019) 134 (Supplement_1): 3112.

https://doi.org/10.1182/blood-2019-126689

Published: 2019

Journal Articles

A Protein-Based Method to Develop Allogeneic Chimeric Antigen Receptor T-Cells

Paul Maciocia, BSc, MBChB, MRCP, Patrycja Wawrzyniecka, Leo Kassimatis, Martin Pule, MD

Blood (2018) 132 (Supplement 1): 700.

https://doi.org/10.1182/blood-2018-99-112544

Published: 2018

Journal Articles

Chimeric Antigen Receptor T-Cells for the Treatment of Gamma-Delta T-Cell Malignancies

Paul Maciocia, BSc, MBChB, MRCP, Patrycja Wawrzyniecka, Leo Kassimatis, Martin Pule, MD

Blood (2018) 132 (Supplement 1): 3338.

https://doi.org/10.1182/blood-2018-99-119774

Published: 2018

Journal Articles

Analysis of T-Cell Receptor Beta-Constant Region Expression for Rapid Assessment of T-Cell Clonality

Paul Maciocia, BSc, MBChB, MRCP, Margarida Neves, MSc, Shimobi Onuoha, PhD, Patrycja Wawrzyniecka, Giuseppe Gritti, Manuela Tosi, Alessia Moioli, Martin Pule, MD, Teresa Marafioti, MD

Blood (2018) 132 (Supplement 1): 2867.

https://doi.org/10.1182/blood-2018-99-112569

Published: 2018

Journal Articles

A Dominant Negative SHP-2 Which Abrogates PD-1 Signalling Pathways and Restores Function of Cytotoxic CAR T Cells

Vania Baldan, PhD, Priyanka Ghongane, MSc, Evangelia Kokalaki, PhD, Wen Chean Lim, PhD, Shimobi Onuoha, PhD, Shaun Paul Cordoba, PhD, Simon Thomas, PhD, Martin Pule, MD PhD

Blood (2017) 130 (Supplement 1): 3190.

https://doi.org/10.1182/blood.V130.Suppl_1.3190.3190

Published: 2017

Journal Articles

T-Cell Engineering For “off-The-shelf” Adoptive Immunotherapy

Laurent Poirot, PhD, Cécile Schiffer-Mannioui, PhD, Brian Philip, Sophie Derniame, PhD, Agnes Gouble, PhD, Isabelle Chion-Sotinel, PhD, Diane Le Clerre, Laetitia Lemaire, Stéphanie Grosse, PhD, Gordon Cheung, Sylvain Arnould, PhD, Julianne Smith, PhD, Martin Pule, MD, Andrew Scharenberg, PhD

Blood (2013) 122 (21): 1661.

https://doi.org/10.1182/blood.V122.21.1661.1661

Published: 2013

Journal Articles

T Cells Engineered For Resistance To Mycophenolate Mofetil Demonstrate Enhanced Expansion and Improved Tumour Control In Immunosuppressed Hosts

James Edward Griffin, MD, Shoa-An Xue, Benjamin J Carpenter, Pedro Velica, PhD, Angelika Holler, Sara Ghorashian, MD, Emma Nicholson, MD, Martin Pule, MD, Ronjon Chakraverty, MD, PhD

Blood (2013) 122 (21): 4486.

https://doi.org/10.1182/blood.V122.21.4486.4486

Published: 2013

Journal Articles

Treatment Of Non-Hodgkin’s Lymphoma With Secondary Central Nervous System Involvement: Encouraging Response Rates Using CNS-Penetrating Idaram Chemotherapy

Paul M Maciocia, MRCP, Mohsin Badat, MB BChir, Simon Cheesman, Jonathan Lambert, MD, Martin Pule, MD, David C. Linch, FRCP, Kirit M Ardeshna, FRCPath

Blood (2013) 122 (21): 4367.

https://doi.org/10.1182/blood.V122.21.4367.4367

Published: 2013

Journal Articles

In Vivo Selection of Mycophenolate Mofetil-Resistant T Cells for Adoptive Immunotherapy.

James Edward Griffin, MD, Ben Carpenter, MD, Emma Nicholson, MD, Shao-an Xue, PhD, Martin Pule, MD, Hans Stauss, MD, PhD, Ronjon Chakraverty, MD, PhD

Blood (2012) 120 (21): 3008.

https://doi.org/10.1182/blood.V120.21.3008.3008

Published: 2012

Journal Articles

CD19-Redirected Cytotoxic T Cells Prevent Engraftment of Primary Human Leukemia Cells In Vivo.

Silke Landmeier, PhD, Bianca Altvater, PhD, Sibylle Pscherer, Jutta Meltzer, Josef Vormoor, MD, FRCPCH, Juan F Vera, MD, Martin Pule, MD, Marc Hotfilder, PhD, Heribert Juergens, MD, Claudia Rossig, MD

Blood (2009) 114 (22): 3025.

https://doi.org/10.1182/blood.V114.22.3025.3025

Published: 2009

Journal Articles

Leukemia Targeting Via Cytotoxic T Cells Expressing a CD33 Specific Chimeric Receptor.

Aurelie Dutour, PhD, Dean Lee, MD, PhD, Stephanie Napier, Helen Finney, PhD, Martin Pule, MD, William Choi, Malcolm Brenner, MB, PHD, Raphael Rousseau, MD, PHD

Blood (2006) 108 (11): 453.

https://doi.org/10.1182/blood.V108.11.453.453

Published: 2006

Journal Articles

Genetically Modified Her2 -Specific T Cells Recognize Low and High Her 2 Expressing Breast Cancer Cells.

Nabil M. Ahmed, MD, MSc, Maheshika Ratnayake, Martin Pule, MD, Cliona M. Rooney, PhD, Helen E. Heslop, MD, Stehpen M. Gottschalk, MD

Blood (2005) 106 (11): 5540.

https://doi.org/10.1182/blood.V106.11.5540.5540

Published: 2005

Journal Articles

Fas Down-Modulation in Epstein Barr Virus (EBV)-Specific Cytotoxic T-Lymphocytes (CTLs) Reduces Their Sensitivity to Fas/Fasl-Induced Apoptosis.

Gianpietro Dotti, MD, Barbara Savoldo, MD, Martin Pule, MD, Karin C. Straathof, MD, Ettore Biagi, MD, Yvon Eric, Sthephane Vigoroux, MD, Cliona M. Rooney, PhD, Malcolm K. Brenner, MD, PhD

Blood (2004) 104 (11): 2647.

https://doi.org/10.1182/blood.V104.11.2647.2647

Published: 2004

NARROW

Therapy of Paediatric B-ALL with a Fast Off Rate CD19 CAR Leads to Enhanced Expansion and Prolonged CAR T Cell Persistence in Patients with Low Bone Marrow Tumour Burden, and Is Associated with a Favourable Toxicity Profile

Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study

Generation of a Highly Sensitive CD22 CAR

Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study

Phase 1 First-in-Human Study of AUTO2, the First Chimeric Antigen Receptor (CAR) T Cell Targeting APRIL for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

A Protein-Based Method to Develop Allogeneic Chimeric Antigen Receptor T-Cells

Chimeric Antigen Receptor T-Cells for the Treatment of Gamma-Delta T-Cell Malignancies

Analysis of T-Cell Receptor Beta-Constant Region Expression for Rapid Assessment of T-Cell Clonality

A Dominant Negative SHP-2 Which Abrogates PD-1 Signalling Pathways and Restores Function of Cytotoxic CAR T Cells

T-Cell Engineering For “off-The-shelf” Adoptive Immunotherapy

T Cells Engineered For Resistance To Mycophenolate Mofetil Demonstrate Enhanced Expansion and Improved Tumour Control In Immunosuppressed Hosts

Treatment Of Non-Hodgkin’s Lymphoma With Secondary Central Nervous System Involvement: Encouraging Response Rates Using CNS-Penetrating Idaram Chemotherapy

In Vivo Selection of Mycophenolate Mofetil-Resistant T Cells for Adoptive Immunotherapy.

CD19-Redirected Cytotoxic T Cells Prevent Engraftment of Primary Human Leukemia Cells In Vivo.

Leukemia Targeting Via Cytotoxic T Cells Expressing a CD33 Specific Chimeric Receptor.

Genetically Modified Her2 -Specific T Cells Recognize Low and High Her 2 Expressing Breast Cancer Cells.

Fas Down-Modulation in Epstein Barr Virus (EBV)-Specific Cytotoxic T-Lymphocytes (CTLs) Reduces Their Sensitivity to Fas/Fasl-Induced Apoptosis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only